Evidence map›Paper›PMID 41003650›Full record

ArticleEpilepsia open2025

The challenge of ultra-rarity: Dual diagnosis of Lafora disease and developmental encephalopathies linked to TRIO and SHANK3 pathogenic variants.

Lorenzo Muccioli, Francesca Bisulli, Raffaella Minardi, Maria Lucia Valentino, Micaela De Simone, Rodrigo Almeida Paroni, Edward Cesnik, Elisa Fallica, Luigi Bonan, Eleonora Pizzi and 3 more

Abstract readCase Reports
In one paragraph

Article in Epilepsia open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Lorenzo MuccioliIRCCS Istituto delle Scienze Neurologiche di Bologna (Full Member of the ERN EpiCARE), Bologna, Italy.ORCID https://orcid.org/0000-0001-6827-0099
Francesca BisulliIRCCS Istituto delle Scienze Neurologiche di Bologna (Full Member of the ERN EpiCARE), Bologna, Italy.ORCID https://orcid.org/0000-0002-1109-7296
Raffaella MinardiIRCCS Istituto delle Scienze Neurologiche di Bologna (Full Member of the ERN EpiCARE), Bologna, Italy.
Maria Lucia ValentinoIRCCS Istituto delle Scienze Neurologiche di Bologna (Full Member of the ERN EpiCARE), Bologna, Italy.
Micaela De SimoneCenter for Research on Epilepsy in Pediatric Age (CREP) and Child Neuropsychiatry Unit, University Hospital of Verona (Full Member of the ERN EpiCARE), Verona, Italy.
Rodrigo Almeida ParoniCenter for Research on Epilepsy in Pediatric Age (CREP) and Child Neuropsychiatry Unit, University Hospital of Verona (Full Member of the ERN EpiCARE), Verona, Italy.
Edward CesnikNeurology Unit, University Hospital of Ferrara, Ferrara, Italy.
Elisa FallicaNeurology Unit, University Hospital of Ferrara, Ferrara, Italy.
Luigi BonanDepartment of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.
Eleonora PizziIRCCS Istituto delle Scienze Neurologiche di Bologna (Full Member of the ERN EpiCARE), Bologna, Italy.ORCID https://orcid.org/0000-0002-4342-0772
DEFEAT‐LD Study Group
Gaetano CantalupoCenter for Research on Epilepsy in Pediatric Age (CREP) and Child Neuropsychiatry Unit, University Hospital of Verona (Full Member of the ERN EpiCARE), Verona, Italy.
Laura LicchettaIRCCS Istituto delle Scienze Neurologiche di Bologna (Full Member of the ERN EpiCARE), Bologna, Italy.ORCID https://orcid.org/0000-0001-7979-9895

Funding

Fondazione Epilessia LICEMinistero della Salute PNRR-MR1-2022-12376430
6 · The paper itself

Abstract

We report two cases of dual genetic diagnoses involving Lafora disease (LD) and co-occurring neurodevelopmental disorders caused by pathogenic variants in TRIO and SHANK3, respectively. LD is an ultra-rare, autosomal recessive, severe form of progressive myoclonus epilepsy affecting previously healthy children or adolescents. In both patients, the presence of developmental delay, intellectual disability, and behavioral abnormalities was consistent with a primary genetic disorder-TRIO-related neurodevelopmental disorder in one, and Phelan-McDermid syndrome in the other. However, the onset of epilepsy with atypical features, coupled with progressive neurological decline in one patient and a positive family history of LD in the other, prompted the additional diagnosis of LD. These cases illustrate how overlapping clinical presentations can obscure the presence of concomitant genetic conditions, potentially delaying diagnosis and appropriate management. Our findings underscore the importance of considering dual diagnoses and show that phenotypical variability in ultra-rare disorders such as LD may be influenced by concurrent genetic conditions. PLAIN LANGUAGE SUMMARY: This report describes two patients who have both Lafora disease, an ultra-rare, progressive type of epilepsy, and other rare genetic disorders that affect development and behavior. In one case, the patient showed a progressive and unusual neurological deterioration, while the other had atypical epileptic seizures and a family history of Lafora disease. These cases highlight how different genetic conditions can share similar symptoms, making it difficult to identify all the issues a patient may have. Understanding these overlaps is important for proper diagnosis and treatment.

Indexed as

Developmental DisabilitiesLafora DiseaseNerve Tissue ProteinsNeurodevelopmental DisordersAdolescentChildChromosome DisordersFemaleHumansMaleYoung AdultNerve Tissue ProteinsSHANK3 protein, humandouble troublenext‐generation sequencing (NGS)Phelan‐McDermid syndromeprogressive myoclonus epilepsywhole‐exome sequencing (WES)whole‐genome sequencing (WGS)

Identifiers

PMID41003650
PMCPMC12716291

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.